cyrilzakka/clinical-trials huggingface dataset:
Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection

This study aims to collect clinical cases and follow-up data from patients with chronic pulmonary aspergillosis, post-COVID-19 aspergillosis, and post-COVID-19 patients without aspergillosis. Using in vitro assays, we will measure the phagocytic function of neutrophils when stimulated by fungal hyphae, their ability to produce neutrophil extracellular traps (NETs), the expression of cell surface molecules at the time of enrollment, changes in cell surface molecule expression after stimulation with fungal hyphae, and the quantification of autoantibodies in the blood. This research will focus on the short-term (within 3 months), medium-term (6-12 months), and long-term (more than 12 months) changes in cell surface molecules and functions following infection.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed cases include patients diagnosed with pulmonary aspergillosis, acute or subacute Aspergillus infections, and aspergillosis in other anatomical sites (such as sinuses, middle ear, liver). Additionally, this study will enroll patients with chronic obstructive pulmonary disease (COPD), asthma, or those undergoing treatment for pulmonary tuberculosis who continue to exhibit worsening pulmonary radiological findings without a clear etiology, necessitating hospitalization or outpatient care for unexplained community-acquired pneumonia. Patients with bronchiectasis, emphysema, pulmonary fibrosis, or other chronic pulmonary conditions who are under continuous follow-up and treatment at our institution will also be included if clinically diagnosed with aspergillosis.

The control group will consist of patients who, based on clinical evidence, have no history of prior exposure to Aspergillus or aspergillosis infection after contracting COVID-19.

Exclusion Criteria:

* Individuals aged below 20, pregnant women, patients with advanced-stage (stage II and above) lung cancer, individuals diagnosed with malignancies, patients with mental health disorders requiring consent from a legal guardian for participation, and those in critical end-stage conditions.
Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia

In the current situation it is of great importance to discover a safe, cost-effective and available treatment strategy in order to limit the rapidly spreading SARS-Cov-2. Recent studies have shown that hydroxychloroquine could have a role in the treatment of infected patients. It is however not very likely that hydroxychloroquine alone could be adequate for treatment of Covid-19 disease. Effective therapy that prevents the virus entrance should contain at least TMPRSS2 inhibitor or a competitive inhibitor of viral ACE 2 binding. The use of bromhexine at the dose adequate to selectively inhibit the TMPRSS2, resulting in preventing of viral entrance via TMPRSS2-specific pathway, coud be an effective treatment of Covid-19. In our study we would like to explore the therapeutic potential of bromhexin and hydroxychloroquine in Covid-19 patients.

Hypothesis

1. Combined treatment with bromhexin and hydroxychloroquine shortens the course of disease in hospitalized Covid-19 patients compared to hydroxychloroquine alone.
2. Combined treatment with bromhexin and hydroxychloroquine lowers the incidence of secundary pulmonary infections in hospitalized Covid-19 patients compared to hydroxychloroquine alone.
3. Combined treatment with bromhexin and hydroxychloroquine decreases the need for ICU admission in hospitalized Covid-19 patients compared to hydroxychloroquine alone.


Eligibility Criteria:
Inclusion Criteria:

* age \> 18 years,
* confirmed infection (positive PCR from nasopharyngeal swab),
* fullfilled hospital admission criteria

Exclusion Criteria:

* pregnancy,
* known allergy for bromhexine or hydroxychloroquine,
* epilepsy,
* prolonged QTc interval,
* Child C liver disease,
* dementia,
* psychoorganic syndrome,
* terminal chronic disease
Evaluating The Effectiveness Of Structured Psychosocial Counseling On Mental Health And FI Individuals With Low Vision

Vision impairments affect 2.2 billion people worldwide, including 36 million who are blind and 217 million with moderate-to-severe visual impairment. In the US, age-related vision loss is a leading cause of disability among older adults.

With increasing longevity, global blindness rates are expected to triple, and moderate-to-severe vision impairment rates to double in 30 years. The study aims to assess the effects of structured psychosocial counseling on mental health (depression, anxiety) and functional independence in individuals with low vision. Additionally, it seeks to evaluate the overall impact on quality of life (QoL) following the counseling intervention. A randomized controlled trial will be conducted at Superior University Lahore.

Eligibility Criteria:
Inclusion Criteria:

* Individuals aged 18 to 80 years.
* Both male and female
* Individuals diagnosed with low vision, defined as a visual acuity of less than 6/18 but equal to or better than 3/60 in the better eye with best correction.
* Individuals having visual acuity 6/60, Counting fingers or light perception.
* Individuals experiencing symptoms of depression or anxiety as assessed through a validated screening tool.
* Individuals reporting reduced functional independence in daily activities due to low vision.

Exclusion Criteria:

* Unable to provide informed consent.
* Diagnosed with severe psychiatric disorders such as schizophrenia, bipolar disorder, or severe post-traumatic stress disorder.
* Existing involvement in similar counseling programs.
* Presence of medical conditions or disabilities.
* Pregnant individuals if pregnancy-related complications or responsibilities could interfere with participation in the intervention.
DIR/ Floortime™ Parent Training Intervention for the Children With Developmental Disabilities

The objective of this study is to test whether adding the parent training program using the relationship-based approach could help the children with development disabilities (DDs) would confer additional benefits over routine clinical care available to both groups in terms of improving their development and reducing behavior problems.

The objective of this study is to test whether adding the parent training program using the relationship-based approach could help the children with development disabilities (DDs) would confer additional benefits over routine clinical care available to both groups in terms of improving their development and reducing behavior problems.

The study treatment involves intervention entirely with parents of children with DDs, rather than directly with the children themselves. Before the first session, all parents in the intervention group had to learn about DIR/ Floortime™ model approach through 1 - hour one on one coaching (at the beginning oft the study, the end of 1st and 3rd month) and through 2 hours DVD lecture and a pocket book. The parent in the intervention group will be asked to carry out FloortimeTM together with using Floortime strategies during daily activities a minimum of 15 hour per week. Meanwhile, the children in the control groups will continue their routine care. The baseline assessment and follow up time schedule were similar to those of the intervention group.

Eligibility Criteria:
Inclusion Criteria:

The children with developmental disabilities :

1. age between 2 - 6 years of age
2. ambulatory
3. living with the primary caregiver for at least 6 months.

Exclusion Criteria:

The children are excluded if :

1. autism
2. deaf
3. blind
4. serious medical problems (e.g. severe congenital heart disease, intractable seizure (a seizure frequency of at least one attack per month during six months despite receiving two anticonvulsant drugs)
5. their parents : not literate, has known chronic psychiatric, or physical illness
Remote Blood Pressure Management Clinical Application Research

Recruit patients with essential hypertension and randomly divide them into three groups. For 24 months, observe the patient's blood pressure level and blood pressure compliance rate,Risk assessment, etc.

Recruit patients with essential hypertension and randomly divide them into three groups. One group through remote blood pressure management platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders;One group is distributed a set of electronic sphygmomanometers , and the blood pressure is recorded by themselves following routine community hypertension management; one group follows routine community hypertension management. For 24 months, observe the patient's blood pressure level and blood pressure compliance rate,Risk assessment, etc. The main technical difficulties and problems to be solved: Widely popularize remote blood pressure based on "Cloud Sharing Smart Cabinet" Management mode. Innovation point: Provide primary hospitals with an intelligent, simple and efficient innovative tool for the management of residents chronic diseases, and improve the management level of chronic diseases in my country promotly; adopt intelligent terminal equipment to realize automatic data collection and transmission to ensure patient real blood pressure data timely and continuously, providing data reference and basis for academic research and the prevention and treatment of chronic diseases, and promoting scientific research in the prevention and treatment of chronic diseases in my country.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of primary hypertension
* Must be aged at ≥18 years old and ≤75 years old
* Must have a smart phone and have the ability to use smart devices
* Must be local permanent resident population who volunteered to participate in the study and received a 2-year follow-up
* Must sign informed consent

Exclusion Criteria:

* Participated in other clinical trials within 4 weeks before the start of this study
* The systolic blood pressure in the office was ≥180 mmHg, and/or the diastolic blood pressure was ≥110 mmHg
* Uremia, creatinine\>250umol/l
* History of acute heart disease in the past three months
* Terminal diseases such as malignant tumors
* Severe cognitive impairment
* Severe diabetes patients (glycated hemoglobin\>11%)
* Severe valvular heart disease, cardiomyopathy, and poor heart function
* Atrial fibrillation and atrioventricular block
* Arm circumference \>35cm or \<26cm
* Spouse or relatives have been included in this research
* Pregnant or breastfeeding women
* Live in an unfixed state
An Evaluation of a Social Network Intervention for Primary and Secondary Prevention of Opioid Overdoses

The purpose of this study is to pilot and implement a peer mentor intervention focused on overdose prevention and care.

The intervention consists of 3 sessions. During the first and second session, each participant will meet individually with a trained staff member. In the 3rd session, the participant will invite a social network member to attend the session, and these 2 participants will meet with a trained staff member.

The specific aims of the study are:

1. Conduct a pilot of an HIV/HCV/overdose prevention and care intervention for people who use opiates.
2. Evaluate the feasibility of collecting donated drug preparation containers (i.e., cookers) to assess the presence of fentanyl, HCV, and HIV.
3. Conduct a randomized controlled trial to assess efficacy of the experimental Peer Mentor condition on (a) overdose prevention and care education to drug network members, (b) naloxone availability, and (c) drug treatment readiness and entry.

There are two types of participants: Index participants and network participants. Both type of participant will currently used opiates. Participants will take part in a baseline visit and up to 3 follow-up visits. Index participants will be randomized into the intervention or control arm of the study.

Eligibility Criteria:
Inclusion Criteria for Index participants:

* self-reported use of opiates including heroin, fentanyl, or prescription opiates to get high at least 2 times in the last two weeks;
* willing to invite a network member who uses drugs to the study;
* ages 18-years or older;
* living in the Baltimore metropolitan region, and
* not previously enrolled in the study or currently enrolled in another Lighthouse study.

Inclusion Criteria for network participants:

* self-reported use of illicit injecting or non-injecting opiates at least 2 times in the last two weeks;
* sees the Index participant 2 or more times in the past week;
* ages 18 years or older; and
* living in the Baltimore metropolitan region.

Exclusion Criteria:

* Index participants may not take part in the study as a Network participant.
* Network participants may not take part in the study as an Index participant.
The Heat Study: 2 Year Lifestyle Intervention in Overweight Women to Encourage Weight Management

The purpose of this trial is to determine the most cost effective programme for overweight and obese individuals to maintain weight loss over a 2 year period.

Although short term weight loss is often achievable in overweight individuals, long term maintenance is generally poor. The researchers urgently need new information regarding the most cost effective programme(s) for maintenance of weight loss. This study will recruit 200 women and compare two approaches for providing support: one with intensive health professional support, the other peer group support facilitated by a research nurse with frequent 'weigh- ins'. The researchers will also compare two different diets one a high carbohydrate, high fibre, low glycaemic index diet versus one relatively high in monounsaturated fat and protein and low in glycaemic load.

Eligibility Criteria:
Inclusion Criteria:

* Female participants
* Aged 25 to 70
* Those who have intentionally lost more than or equal to 5% of initial body weight in the previous 6 months will be recruited
* Objective evidence that volunteers were overweight or obese and have lost weight will be obtained from doctors records

Exclusion Criteria:

* Presence of major illness including cancers
* Established cardiovascular disease or stroke
* Diabetes
* Gestational diabetes
* Renal disease
* Malabsorption disorders
* Thyroid disorders
* Major psychiatric disorders
* Taking weight loss medication or medications known to cause weight gain
* Planning a pregnancy in the next 2 years
* Those who do not intend to be in the area for the next 2 years
Increasing Physical Activity in Persons With Depression

Pilot study to assess a multi-component intervention to increase physical activity in persons with depression.

The research project is a pilot study to assess the effects of a multi-component intervention in increasing physical activity among persons with depression. Individuals meeting inclusion/exclusion criteria will be enrolled in the 12-week intervention. Intervention components will include self-monitoring, Active Living counseling, and facility access. Blood samples will be collected at baseline. Assessments (anxiety, stress, sleep) and sample collection will also occur at 2 time points during the intervention (Weeks 7 and 13). Changes in physical activity will be assessed using Fitbits to measure weekly minutes of moderate/vigorous activity.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-65 years
* Positive depression screen (Patient Health Questionnaire \[PHQ-9\]) or current antidepressant treatment
* Report \<150 minutes of weekly moderate-to-vigorous physical activity (MVPA) on the Exercise Vital Sign (EVS)
* Written and verbal fluency in English

Exclusion Criteria:

* Medical condition contraindicating physical activity participation
* Cognitively unable to give informed consent
* Non-English speaking
Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult

The purpose of this study is to evaluate the safety and efficacy of a novel topical treatment for dry scalp conditions, including dandruff, seborrheic dermatitis, and atopic dermatitis. The study investigates clinical improvements in symptom severity, participant experience with the treatment, and changes in the scalp microbiome before and after use. By studying this treatment, the investigators aim to provide children and adults with a natural, effective option for managing dry scalp conditions.

This study evaluates the safety and efficacy of a novel topical scalp treatment for dry scalp conditions, including dandruff, seborrheic dermatitis, and atopic dermatitis. The treatment contains Lactobacillus sp., honey, and turmeric in an emollient base, hypothesized to alleviate symptoms by addressing microbial imbalances, reducing inflammation, and promoting scalp hydration.

The study will enroll 15-40 pediatric participants aged 1-17 years and 20-40 adults aged 18 and older, all clinically diagnosed with dry scalp. All participants will apply the treatment over a 14-day period. Adults will use the treatment daily, while pediatric participants will apply it 2-3 times weekly. Other scalp therapies will be discontinued during the study period.

The study aims to explore the treatment's potential to improve clinical severity, enhance quality of life, and positively impact the scalp microbiome, providing a natural, effective option for managing dry scalp conditions.

Eligibility Criteria:
Inclusion Criteria:

1. Age 1 year (or corrected age of 1 year, for those born prematurely) to 17 years for children, and adults 18 and older
2. Patients with dry scalp and dandruff symptoms as determined by a board-certified Dermatologist, Allergist, or Pediatrician
3. Good general health
4. Participant and/or their parents are able to read, write, and understand study materials in English

Exclusion Criteria:

1. Infants younger than 1 year old
2. Patients diagnosed with other scalp diseases such as psoriasis, tinea capitis, and pediculosis capitis
3. Systemic steroid or oral antibiotic use during the past two months
4. Allergy to any of the preparation components
A Longitudinal Study in Parkinson's Disease (PD) Patients

This is a longitudinal study in patients with Parkinson's Disease (PD) carriers of a genetic mutation - substitution of gly with ser in position 2019 (G2019S) in the leucine-rich repeat kinase 2 (LRRK2) gene. The purpose of this study is to explore the association between genetic mutations in the known genes and their influence on disease manifestation over few years of follow up


Eligibility Criteria:
Inclusion Criteria:

* parkinson'd disease patients that already participated in a pasr cross sectional study

Exclusion Criteria:

* subjects with cognitive decline by the parameters defined in Diagnostic and Statistical Manual of Mental Disorders (DSM)- IV
* subjects with psychiatric disorder
* subjects unable to sign a consent form
2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects

This is a single-center, randomized, double-blind, placebo-controlled, sequential, multiple-dose study. The study will be conducted in two parts: Part A (6 cohorts of healthy adults receiving evening dosing) and Part B (one cohort of elderly adults receiving evening dosing).


Eligibility Criteria:
Included:

* Healthy males or females, ages 18 to 55 years (Part A) or 65 to 80 years (Part B)
* Who report typical time in bed 7.5 to 9 hours
* Who report typical bedtime 22:00 - 24:00 and typical wake time 06:00 - 08:00
* Who report typical sleep latency of \<= 30 minutes
* All females must be of non-childbearing potential, or subjects who have been sterilized surgically or who are otherwise proven sterile. Females must have a negative serum beta-human chorionic gonadotropin (Beta-hCG) test result at Screening and a negative urine pregnancy test at Baseline.
* Body mass index BMI \> 18 and 32 kg/m2 at Screening

Excluded:

* Performed shift work within 2 weeks prior to Screening
* Had taken a flight across three or more time zones in the 7 days prior to Screening
* Female subjects who are nursing
* With a history of gastrointestinal surgery (hepatectomy, nephrectomy, digestive organ resection, etc.) that may affect PK profile of E2006
* With a known history of clinically significant drug or food allergies or presently experiencing significant seasonal allergy
* Hypersensitivity to the study drug or any of the excipients
Surface EMGdi Evaluate the Efficacy of Pulmonary Rehabilitation in Patients With COPD: a Multi Center Prospective Study

Pulmonary rehabilitation is recognized as a core component of the management of individuals with chronic obstructive respiratory disease, which has become first-line treatment besides drug therapy. However, in the current clinical evaluation system of pulmonary rehabilitation, there is still a lack of simple, objective index,which can be monitored at any time.Neural respiratory drive , as an important physiological index, is closely related to the symptoms and the severity of the disease. It may be a sensitive indicator to evaluate the effectiveness of pulmonary rehabilitation. Surface EMGdi can accurately evaluate neural respiratory drive , its detection is non-invasive, simple and safety . In recent years, with the development of signal detection and analysis technology, EMG recording is more stable, but as the related research samples were low, surface diaphragm EMG has not yet the establishment of standardization. Therefore, based on the previous work, the project was carried out in a multicenter randomized controlled study,in which the stable stage of COPD patients were included in different ways of pulmonary rehabilitation training, a comprehensive clinical assessment will be conducted before and after training. Compared with the traditional evaluation methods and standard esophageal diaphragmatic electromyography, surface EMGdi detect the changes of neural respiratory drive in patients with COPD,that can help to explore the application value of surface EMGdi in the assessment of chronic obstructive pulmonary disease with pulmonary rehabilitation, to provide a basis for the promotion of the diaphragm and the optimization of pulmonary rehabilitation program.

The patients with COPD will participate in a rehabilitation program for 52 weeks.

Participants in the proposed study will be randomly programmed into one of four intervention groups:

1. Neither cycle training nor inspiratory muscle training.
2. Cycle training program alone (performing on calibrated stationary cycle ergometer).
3. Inspiratory muscle training alone (performing on threshold loading device).
4. Combined cycle training and inspiratory muscle training(performing on calibrated stationary cycle ergometer and threshold loading device).

Eligibility Criteria:
Inclusion Criteria:

* Patients aged over 40 years old.
* Patients with pulmonary function test of forced expiratory volume at one second(FEV1)/forced vital capacity(FVC) \< 70%.
* Patients in a clinically stable state
* Patients who signed informed consent.
* No participation in other pulmonary rehabilitation program within the previous 2 months.

Exclusion Criteria:

* Patients with signs of an airway infection.
* Patients with metabolic disease and serious cardiovascular disease.
* Patients with Multiple pulmonary bulla.
* Patients with poor compliance.